Clinical Evidence

Discover our latest testimonials and publications

Oxford University Hospitals NHS Foundation Trust - Oxford, UK

Ian Smith

Screening Laboratory and Point of Care Testing Manager

One of the main benefits of Sight OLO is that it’s easy to maintain. Because it has a cartridge-based system that stores all the reagents within a single cartridge, it doesn’t require buffer packs or calibrations that may require further maintenance. Adding Sight OLO to our armory of point-of-care diagnostics can both improve and expedite the treatment decision process for our healthcare providers.

Clinton Family Care - Mississippi, USA

Dr. David B. Wheat MD

Physician, POL

The number one reason to deploy OLO was to reduce overhead cost. With OLO, we do not need to manage all the reagents, diluents and cleaning supplies, in addition to the quality control materials, which can be quite a lot of administrative work for a lean staff like ours. The real value is customer service, and Sight is just exceptional. It’s so far beyond anything I’ve seen in the industry.

Partner Liberia - Liberia

Michael D. Davis, RRT, PhD, FAARC


One of the primary differences switching from manual blood work to Sight OLO is that we reverse the paradigm on context versus quantitative data. Now, we are trying to run as many CBCs as we possibly feel is necessary, because this test helps us make informed decisions on our patients. OLO has helped improve the quality of care we provide to patients here. In Liberia, nothing ever goes as planned, but installation and training went surprisingly well. If you can make it work in Liberia, you can really make it work anywhere.

Boston Children's Hospital - Boston, US

Dr. Carlo Brugnara

Director, Hematology Lab

OLO’s performance is comparable to analyzers that are 50 times bigger and much more complicated to operate. The ability to take that much analytical power outside of the central lab and bring it to any setting where you can perform a CBC analysis in minutes has huge implications for hospital wards, such as oncology clinics, emergency rooms and beyond.

Sheba Tel Hashomer Medical Center - Tel Aviv, ISR

Dr. Ram Doolman

Director, Laboratories Division & Automated Mega-Laboratory

The Sight OLO successfully completed a comprehensive evaluation study at the Sheba Tel Hashomer Medical Center. The evaluation compared OLO’s performances to a state-of-the-art analyzer and experienced microscopists, across a wide clinical range. OLO’s excellent performance exceeded predefined acceptance criteria in all aspects. Following the evaluation, we have started a research collaboration with the aim to explore the diagnostic potential of visual signatures in the blood images among different patient populations, including those with COVID-19.

Nicklaus Children's Hospital - Miami, US

Dr. Steven Melnick

Chief, Department of Pathology

To treat children in our urgent care centers, a CBC is essential. OLO represents a major innovation in our laboratories’ CBC analysis: low blood volume (finger-prick) sampling for a five-part differential with flagging. It’s a truly welcome development. At current volumes, we believe OLO could substantially reduce our costs.

Oldham Integrated Care Centre - Manchester, UK

Dr. Alan Nye

Executive Director, Pennine MSK Partnership

Thanks to OLO and the use of POC we were able to create a new patient pathway to treat vulnerable non-COVID-19 patients away from the main Oldham hospital. The training we did to learn how to use OLO was straightforward and comprehensive. OLO is an intuitive machine with on-screen step by step instructions which makes the process easy to remember. In addition, the OLO rejects samples that are not properly prepared and explains what went wrong, which helps us learn and improve. OLO also doesn’t require any maintenance, a game changer allowing us more time to care for patients.

Medica Health Centre, The Traveller’s Clinic

Dr. Zacarias


In Hermosillo, we see many patients who have to travel far to see us. We often rely on the patient’s complete blood count results to help us differentiate between bacterial or viral infection and identify whether additional tests are necessary to arrive at an informed diagnosis. Many of them have difficulties going to a lab for a blood test, waiting for the results and then coming back to see us again. Sight OLO has been extremely beneficial to our practice because patients can get their CBC results, a diagnosis and a treatment plan within the same appointment, and we’re able to generate additional revenues from the CBC tests done in our office.



July 15, 2021

An Artificial Intelligence-Assisted Diagnostic Platform for Rapid Near-Patient Hematology

Hematology analyzers capable of performing complete blood count (CBC) have lagged in their prevalence at the point-of-care. Sight OLO® is a novel hematological platform which provides a 19 parameter, five-part differential CBC, and is designed to address the limitations in current point-of-care hematology analyzers using recent advances in artificial intelligence (AI) and computer vision.


August 31, 2021

Simplicity for use- Sight OLO® Hematology Analyzer

At Sight, we keep things simple. From the AI-driven design of our blood test technology to the ease of operating our machines and our quick turnover time, we streamline the typical manual blood staining workflow. With our self-contained OLO hematology analyzer and its disposable cartridge, fast and accurate Complete Blood Count (CBC) results are minutes away, resulting in rapid diagnostics leading to treatment of health concerns.

Pre-print manuscript:

August 31, 2021

Real-world evaluation of AI driven COVID-19 triage for emergency admissions

Rapid and accurate screening can play a vital role in reducing the spread of COVID-19 and ensuring that patients receive timely and appropriate treatment upon arrival at hospital. This study demonstrates that CURIAL-Rapide can be used in combination with near-patient Full Blood Count (FBC) analysis for rapid, lab-free screening and may reduce the number of COVID-19-negative patients triaged to enhanced precautions clinical areas.

Regulatory Submissions

July, 20th 2020
OLO is listed in the ARTG (Australian Register of Therapeutic Goods)
March, 29th 2021
Received Canada Class II Medical Device License
November 30th, 2020
Sight received marketing authorization for OLO in the UAE
November, 1st 2019
FDA 510 (k) Clearance
October 2019
OLO is listed in ANVISA (the National Health Surveillance Agency in Brazil)
OLO is listed in the Registry of Medical Devices and Accessories in Israel